跳到主要內容區
 
:::
  1. 首頁
  2. 研究單位
  3. 中藥化學研究組

蔡耿彰（Tsai, Keng-Chang）

蔡耿彰實驗室生活照姓名：蔡耿彰（Tsai, Keng-Chang）
職稱：副研究員
            資訊中心主任
            材料移轉辦公室主任
            國立成功大學藥學系暨臨床藥學與藥物科技研究所 兼任副教授 (2021/08/01~now)
            臺北醫學大學 醫學檢驗暨生物技術學系所 醫學生物科技博士學程 兼任副教授 (2016/05/01~now)
電話：02-2820-1999轉6241(Office)、6251(Lab)
E-mail :tkc@nricm.edu.tw

學歷:
國立清華大學 生命科學系 博士 (2000/09~2005/06)

主要經歷:
國防醫學院 病理組 兼任副教授 (2021/08/01~2022)
衛生福利部國家中醫藥研究所 智財技轉中心主任(2020/11~2021/12)
衛生福利部國家中醫藥研究所 助理研究員(2013/07~2015/11)
教育部國立中國醫藥研究所 助理研究員(2011/08~2013/07)
消基會中醫藥委員會委員(2014)
中央研究院基因體中心 博士後研究員(2005/10~2011/07)
Breadth生物資訊和中草藥資料庫專案經理(2004/02~2005/06)

專長:
中藥免疫調節蛋白、中藥研發、噬菌體表達抗體或胜肽庫、抗體工程、小分子藥物開發、AI人工智慧藥物設計、中草藥小分子資料庫、結構生物資訊。

近期研究方向簡介:
       我們實驗室分成兩組Wet Lab和Dry Lab，研究上我們主要是利用嗜菌體表達中藥蛋白, 抗體或胜肽，透過AI人工智慧藥物設計方法來研究中草藥，最終目的是希望可以尋找中草藥應用於有興趣的標靶蛋白或篩選抗小分子或標靶蛋白之抗體，目前興趣上可分為五種:

  1. 中藥免疫調節蛋白研發與應用(Fungal immunomodulatory proteins (FIPs))
  2. 透過噬菌體表達(中藥)抗體庫平台(Phage Display Antibody Library)應用於癌症標靶蛋白、精準醫學標靶蛋白、免疫療法檢查點蛋白之篩選分離及生技應用。
  3. 設計奈米抗體(Nanobody, VHH)偵測中藥材細辛之馬兜鈴酸(Aristolochic acids, AAs)、紅麴之橘黴素(Citrinin, CT)、中藥材黴變生成赭麴毒素(Ochratoxin A, OTA)和黃麴毒素(Aflatoxin B1, AFB1)..等。
  4. 設計中藥或植物新藥免疫調節劑。
  5. 透過噬菌體表達胜肽庫和中草藥的萃取物進行親和性篩選(Affinity Selection)，再經由實驗結合AI人工智慧找出最有可能的作用的胜肽序列反釣出重要的標靶蛋白(Fishing Target Protein)來進行疾病的診斷或分析。
  6. 設計藥效基團(Pharmacophore)反釣藥物和反釣標靶蛋白資料(rPharma)。
  7. 建立龐大中草藥(天然產物)資料庫(iTCM)從中醫藥典收集整理連接到疾病、標靶蛋白、藥物分子、天然產物化合物資料、藥效基團篩選，分子對接(Docking)。
 

研討會:  第31屆天然藥物研討會 藥學暨中醫藥學門成果發表會 中藥組第一名

中文期刊:

  • 化工資訊與商情第三十七期目錄 藥物資訊學在藥物開發的應用.(2006). 蔡耿彰 ; 蔡永裕 ; 陳廷碩
  • Wang-Chuan Chen*, Keng-Chang Tsai, Li-Wei Lin, Hui-Hsiung Lin, and  Chun-Chuan Shih. (2015) Investigation of Tyrosinase Inhibition by Chinese Herbal Medicine Small Molecules as Skin-whitening Ingredients, Taiwan Journal of Chinese Medicine. 13(1):29-42. (臺灣中醫醫學雜誌)
  • Li-Wei Lin, Yune-Fang Ueng, Keng-Chang Tsai, Hung-Ju Hsu, Chun-Chuan Shih, and Wang-Chuan Chen.* (2015) Investigation of Interaction between Shu-Gin-Hwai-Shen-tang and Anticoagulant Warfarin from the Perspective of Structural Biology, Taiwan Journal of Chinese Medicine. 13(1):1-12. (臺灣中醫醫學雜誌)
      NCBI PubMed : Keng-Chang Tsai (Please click!!) 
      Google Scholar : Keng-Chang Tsai (Please click!!)

    (*代表corresponding author)

  1. Yu KH, Kuo CY, Wu IT, Chi CH, Tsai KC, Kuo PC, Zeng JW, Hung CC*, Hung HY*. Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo. Eur J Pharmacol 2023:176146. https://doi.org:10.1016/j.ejphar.2023.176146
  2. Wei WC, Tsai KC(co-first), Liaw CC, Chiou CT, Tseng YH, Liao GY, Lin YC, Chiou WF, Liou KT, Yu IS, Shen YC*, Su YC*. NRICM101 ameliorates SARS-CoV-2-S1-induced pulmonary injury in K18-hACE2 mice model. Front Pharmacol 2023, 14:1125414. https://doi.org:10.3389/fphar.2023.1125414
  3. Wang HJ, Chen AC, Chen HY, Cheng HC, Kao LT, Lu CK, Tsai KC, Lee IJ, Ueng YF*. Identification of the perpetrator imperatorin in Xin-yi-san-theophylline interaction: observed and predicted herb-drug interaction in rats. J Pharm Pharmacol 2023, 75(9):1225-1236. https://doi.org:10.1093/jpp/rgad054
  4. Tseng HJ, Chen WC, Kuo TF, Yang G, Feng CS, Chen HM, Chen TY, Lee TH, Yang WC*, Tsai KC*, Huang WJ*. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice. Cell Mol Life Sci 2023, 80(4):101. https://doi.org:10.1007/s00018-022-04677-5
  5. Tsai KC, Chen CS, Su JH, Lee YC, Tseng YH, Wei WC*. The Blockade of Mitogen-Activated Protein Kinase 14 Activation by Marine Natural Product Crassolide Triggers ICD in Tumor Cells and Stimulates Anti-Tumor Immunity. Mar Drugs 2023, 21(4). https://doi.org:10.3390/md21040225
  6. Lee YC, Lai GH, Lin TY, Tseng TS, Tsai TH, Chen WC, Lee CC, Tsai KC*. Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testing. J Biol Eng 2023, 17(1):30. https://doi.org:10.1186/s13036-023-00350-y
  7. Chou O, Juang YP, Chao TL, Tsai SF, Chiu PF, Chiou CT, Tsai KC, Chang SY*, Liang PH*, Wong CH*. Isolation of Anti-SARS-CoV-2 Natural Products Extracted from Mentha canadensis and the Semi-synthesis of Antiviral Derivatives. J Nat Prod 2023, 86(6):1428-1436. https://doi.org:10.1021/acs.jnatprod.3c00104
  8. Chiu PF, Lin IC, Lu YL, Chang CN, Chan HY, Lin TS, Tsai KC, Hsieh YSY, Chen MJ, Lin MH*, Liang PH*. Design, structure-activity relationships, and enzyme kinetic studies of tricyclic and tetracyclic coumarin-based sulfamates as steroid sulfatase inhibitors. Bioorg Chem 2023, 138:106581. https://doi.org:10.1016/j.bioorg.2023.106581
  9. Chiang CW, Lin YS, Chang FL, Lin TY, Tsai KC, HuangFu WC*, Lee YC*. Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer. Biochem Biophys Res Commun 2023, 680:161-170. https://doi.org:10.1016/j.bbrc.2023.09.025
  10. Wei WC, Liaw CC, Tsai KC(co-first), Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC*, Su YC*. Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res 2022, 184:106424. https://doi.org:10.1016/j.phrs.2022.106424
  11. Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC*. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res 2022, 184:106412. https://doi.org:10.1016/j.phrs.2022.106412
  12. Tsai KC*, Zhang YX, Kao HY, Fung KM, Tseng TS*. Pharmacophore-driven identification of human glutaminyl cyclase inhibitors from foods, plants and herbs unveils the bioactive property and potential of Azaleatin in the treatment of Alzheimer's disease. Food Funct 2022, 13(24):12632-12647. https://doi.org:10.1039/d2fo02507h
  13. Lin YS, Hsieh SJ, Tsai KC, Cheng MH, Yang TW, Lin TY, Chang FL, Chiang CW, Chen WC, Huang HT*, Lee YC*. Blockade effect of avian-derived anti-VISTA antibodies on immunosuppressive responses. All Life 2022, 15(1):479-489. https://doi.org:10.1080/26895293.2022.2063951
  14. Chang CN, Lin IC, Lin TS, Chiu PF, Lu YL, Narwane M, Liu IC, Hng Y, Tsai KC, Lin MH, Y SYH, Chen MJ, Liang PH*. The Design, Structure-Activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-Tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as Steroid sulfatase inhibitors. Bioorg Chem 2022, 129:106148. https://doi.org:10.1016/j.bioorg.2022.106148
  15. Tung MC, Tsai KC(co-first), Fung KM, Don MJ, Tseng TS*. Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase. RSC Adv 2021, 11(4):2453-2461. https://doi.org:10.1039/d0ra08769f
  16. Tsai KC, Lee YC, Tseng TS*. Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. Front Microbiol 2021, 12:698365. https://doi.org:10.3389/fmicb.2021.698365
  17. Tsai KC, Huang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC*. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother 2021, 133:111037. https://doi.org:10.1016/j.biopha.2020.111037
  18. Lin TY, Tsai TH, Chen CT, Yang TW, Chang FL, Lo YN, Chung TS, Cheng MH, Chen WC, Tsai KC*, Lee YC*. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response. Exp Anim 2021, 70(3):333-343. https://doi.org:10.1538/expanim.20-0178
  19. Kuo TF, Hsu SW, Huang SH, Chang CL, Feng CS, Huang MG, Chen TY, Yang MT, Jiang ST, Wen TN, Yang CY, Huang CY, Kao SH, Tsai KC, Yang G, Yang WC*. Pdia4 regulates β-cell pathogenesis in diabetes: molecular mechanism and targeted therapy. EMBO Mol Med 2021, 13(10):e11668. https://doi.org:10.15252/emmm.201911668
  20. Chern CM, Lu CK, Liou KT, Wang YH, Tsai KC, Chang CL, Chang CC, Shen YC*. Medicarpin isolated from Radix Hedysari ameliorates brain injury in a murine model of cerebral ischemia. J Food Drug Anal 2021, 29(4):581-605. https://doi.org:10.38212/2224-6614.3377
  21. Lee YC, Huang HT, Chang CD, Chen CT, Lin TY, Yang TW, Chang FL, Lu MK, Chiou CT, Chen WC, Pan SL, Tsai KC*. Isolation of anti-VEGF monoclonal antibodies with neutralizing effects from an Astragalus-induced immune antibody library. Int Immunopharmacol 2020, 88:107007. https://doi.org:10.1016/j.intimp.2020.107007
  22. Hng Y, Lin MH, Lin TS, Liu IC, Lin IC, Lu YL, Chang CN, Chiu PF, Tsai KC, Chen MJ, Liang PH*. Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors. Bioorg Chem 2020, 96:103618. https://doi.org:10.1016/j.bioorg.2020.103618
  23. Chang FL, Tsai KC, Lin TY, Yang TW, Lo YN, Chen WC, Chang JH, Lu MK, Chiou CT, Chen PH, Yen Y*, Pan SL*, Lee YC*. Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. Biomed Res Int 2020, 2020:3415471. https://doi.org:10.1155/2020/3415471
  24. Tsai KC, Hung PP, Cheng CF, Chen C, Tseng TS*. Exploring the mode of action of inhibitors targeting the PhoP response regulator of Salmonella enterica through comprehensive pharmacophore approaches. RSC Adv 2019, 9(16):9308-9312. https://doi.org:10.1039/c9ra00620f
  25. Tsai KC, Chiang CW, Lo YN, Chang FL, Lin TY, Chang CY, Chen WC, Lee YC*. Generation and characterization of avian-derived anti-human CD19 single chain fragment antibodies. Anim Biotechnol 2019, 30(4):293-301. https://doi.org:10.1080/10495398.2018.1486323
  26. Tsai KC, Chang CD, Cheng MH, Lin TY, Lo YN, Yang TW, Chang FL, Chiang CW, Lee YC*, Yen Y*. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent. ACS Omega 2019, 4(1):2387-2397. https://doi.org:10.1021/acsomega.8b03072
  27. Wang YH, Liou KT, Tsai KC, Liu HK, Yang LM, Chern CM, Shen YC*. GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice. Toxicol Appl Pharmacol 2018, 357:88-105. https://doi.org:10.1016/j.taap.2018.08.023
  28. Wang PC, Chiu DC, Jan JT, Huang WI, Tseng YC, Li TT, Cheng TJ, Tsai KC, Fang JM*. Peramivir conjugates as orally available agents against influenza H275Y mutant. Eur J Med Chem 2018, 145:224-234. https://doi.org:10.1016/j.ejmech.2017.12.072
  29. Tseng TS, Tu IF, Chen HT, Lin LC, Tsai KC*, Wu SH*, Chen C*. Protein-DNA complex-guided discovery of the antibacterial lead E1 for restoring the susceptibility of Klebsiella Pneumoniae to polymyxin B by targeting the response regulator PmrA. Chem Commun (Camb) 2018, 54(49):6372-6375. https://doi.org:10.1039/c8cc01840e
  30. Kuo LY, Tseng PY, Lin YC, Liaw CC, Zhang LJ, Tsai KC, Lin ZH, Ho HO, Kuo YH*. New Hirsutinolide-Type Sesquiterpenoids from Vernonia cinerea Inhibit Nitric Oxide Production in LPS-Stimulated RAW264.7 Cells. Planta Med 2018, 84(18):1348-1354. https://doi.org:10.1055/a-0647-1901
  31. Hsu PH, Chiu DC, Wu KL, Lee PS, Jan JT, Cheng YE, Tsai KC, Cheng TJ, Fang JM*. Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. Eur J Med Chem 2018, 154:314-323. https://doi.org:10.1016/j.ejmech.2018.05.030
  32. Chang CY, Chang FL, Chiang CW, Lo YN, Lin TY, Chen WC, Tsai KC, Lee YC*. Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope. Viral Immunol 2018, 31(7):492-499. https://doi.org:10.1089/vim.2017.0200
  33. Tseng TS, Tsai KC, Chen C*. Characterizing the structure-function relationship reveals the mode of action of a novel antimicrobial peptide, P1, from jumper ant Myrmecia pilosula. Mol Biosyst 2017, 13(6):1193-1201. https://doi.org:10.1039/c6mb00810k
  34. Kuo TF, Chen TY, Jiang ST, Chen KW, Chiang YM, Hsu YJ, Liu YJ, Chen HM, Yokoyama KK, Tsai KC, Yeh HH, Chen YR, Yang MT, Yang CY, Yang WC*. Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway. Oncogene 2017, 36(39):5484-5496. https://doi.org:10.1038/onc.2017.156
  35. Chiu DC, Lin TC, Huang WI, Cheng TJ, Tsai KC, Fang JM*. Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus. Org Biomol Chem 2017, 15(46):9910-9922. https://doi.org:10.1039/c7ob02374j
  36. Wang PC, Fang JM*, Tsai KC, Wang SY, Huang WI, Tseng YC, Cheng YS, Cheng TJ, Wong CH. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. J Med Chem 2016, 59(11):5297-5310. https://doi.org:10.1021/acs.jmedchem.6b00029
  37. Tseng TS, Wang SH, Chang TW, Wei HM, Wang YJ, Tsai KC, Liao YD, Chen C*. Sarkosyl-Induced Helical Structure of an Antimicrobial Peptide GW-Q6 Plays an Essential Role in the Binding of Surface Receptor OprI in Pseudomonas aeruginosa. PLoS One 2016, 11(10):e0164597. https://doi.org:10.1371/journal.pone.0164597
  38. Tseng TS, Lee YC, Hsiao NW, Liu YR, Tsai KC*. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors. Bioorg Med Chem Lett 2016, 26(2):265-271. https://doi.org:10.1016/j.bmcl.2015.12.043
  39. Tseng TS, Chuang SM, Hsiao NW, Chen YW, Lee YC, Lin CC, Huang C, Tsai KC*. Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. Mol Biosyst 2016, 12(8):2541-2551. https://doi.org:10.1039/c6mb00229c
  40. Tsay HJ, Huang YC, Chen YJ, Lee YH, Hsu SM, Tsai KC, Yang CN, Huang FL, Shie FS, Lee LC, Shiao YJ*. Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO. J Biomed Sci 2016, 23:27. https://doi.org:10.1186/s12929-016-0244-5
  41. Jian JW, Elumalai P, Pitti T, Wu CY, Tsai KC, Chang JY, Peng HP, Yang AS*. Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms. PLoS One 2016, 11(8):e0160315. https://doi.org:10.1371/journal.pone.0160315
  42. Tseng TS, Tsai KC(co-first), Chen WC, Wang YT, Lee YC, Lu CK, Don MJ, Chang CY, Lee CH, Lin HH, Hsu HJ, Hsiao NW*. Discovery of Potent Cysteine-Containing Dipeptide Inhibitors against Tyrosinase: A Comprehensive Investigation of 20 × 20 Dipeptides in Inhibiting Dopachrome Formation. J Agric Food Chem 2015, 63(27):6181-6188. https://doi.org:10.1021/acs.jafc.5b01026
  43. Lo SN, Shen CC, Chang CY, Tsai KC, Huang CC, Wu TS, Ueng YF*. The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition. Drug Metab Dispos 2015, 43(7):1100-1107. https://doi.org:10.1124/dmd.115.063966
  44. Li A, Yang D, Zhu M, Tsai KC, Xiao KH, Yu X, Sun J, Du L*. Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics. Future Med Chem 2015, 7(18):2429-2437. https://doi.org:10.4155/fmc.15.160
  45. Lee YC, Hsiao NW, Tseng TS, Chen WC, Lin HH, Leu SJ, Yang EW, Tsai KC*. Phage display-mediated discovery of novel tyrosinase-targeting tetrapeptide inhibitors reveals the significance of N-terminal preference of cysteine residues and their functional sulfur atom. Mol Pharmacol 2015, 87(2):218-230. https://doi.org:10.1124/mol.114.094185
  46. Lee YC, Chen WC, Liang MH, Lee CH, Tsai KC, Chiang JR, Chiang LC, Chen CC, Chang CY, Lee CH, Leu SJ, Yang YY*. Single chain antibody fragment with serine protease inhibitory property capable of neutralizing toxicity of Trimeresurus mucrosquamatus venom. Biochem Biophys Res Commun 2015, 460(2):170-176. https://doi.org:10.1016/j.bbrc.2015.02.169
  47. Ho CW, Van Meervelt V, Tsai KC, De Temmerman PJ, Mast J, Maglia G*. Engineering a nanopore with co-chaperonin function. Sci Adv 2015, 1(11):e1500905. https://doi.org:10.1126/sciadv.1500905
  48. Chen WC, Tseng TS, Hsiao NW, Lin YL, Wen ZH, Tsai CC, Lee YC, Lin HH, Tsai KC*. Discovery of highly potent tyrosinase inhibitor, T1, with significant anti-melanogenesis ability by zebrafish in vivo assay and computational molecular modeling. Sci Rep 2015, 5:7995. https://doi.org:10.1038/srep07995
  49. Chang YP, Huang CC, Shen CC, Tsai KC, Ueng YF*. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet 2015, 30(5):374-383. https://doi.org:10.1016/j.dmpk.2015.08.006
  50. Hsiao NW, Tseng TS, Lee YC, Chen WC, Lin HH, Chen YR, Wang YT, Hsu HJ, Tsai KC*. Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors. J Chem Inf Model 2014, 54(11):3099-3111. https://doi.org:10.1021/ci500370x
  51. Hong BT, Chen CL, Fang JM*, Tsai KC, Wang SY, Huang WI, Cheng YE, Wong CH. Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors. Bioorg Med Chem 2014, 22(23):6647-6654. https://doi.org:10.1016/j.bmc.2014.10.005
  52. Chen CY, Huang CC, Tsai KC, Huang WJ, Huang WC, Hsu YC, Hsu FL*. Evaluation of the Antihyperuricemic Activity of Phytochemicals from Davallia formosana by Enzyme Assay and Hyperuricemic Mice Model. Evid Based Complement Alternat Med 2014, 2014:873607. https://doi.org:10.1155/2014/873607
  53. Chen CL, Lin TC, Wang SY, Shie JJ, Tsai KC, Cheng YS, Jan JT, Lin CJ*, Fang JM*, Wong CH*. Tamiphosphor monoesters as effective anti-influenza agents. Eur J Med Chem 2014, 81:106-118. https://doi.org:10.1016/j.ejmech.2014.04.082
  54. Lo SN, Chang YP, Tsai KC, Chang CY, Wu TS, Ueng YF*. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol Appl Pharmacol 2013, 272(3):671-680. https://doi.org:10.1016/j.taap.2013.07.005
  55. Lee YC, Tsai KC, Leu SJ, Wang TJ, Liu CY, Yang YY*. Isolation, characterization, and molecular modeling of a rheumatoid factor from a Hepatitis C virus infected patient with Sjögren's syndrome. ScientificWorldJournal 2013, 2013:516516. https://doi.org:10.1155/2013/516516
  56. Yu CM, Peng HP, Chen IC, Lee YC, Chen JB, Tsai KC, Chen CT, Chang JY, Yang EW, Hsu PC, Jian JW, Hsu HJ, Chang HJ, Hsu WL, Huang KF, Ma AC, Yang AS*. Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. PLoS One 2012, 7(3):e33340. https://doi.org:10.1371/journal.pone.0033340
  57. Tsai KC, Jian JW, Yang EW, Hsu PC, Peng HP, Chen CT, Chen JB, Chang JY, Hsu WL, Yang AS*. Prediction of carbohydrate binding sites on protein surfaces with 3-dimensional probability density distributions of interacting atoms. PLoS One 2012, 7(7):e40846. https://doi.org:10.1371/journal.pone.0040846
  58. Chen HJ, Shen YC, Lin CY, Tsai KC, Lu CK, Shen CC, Lin YL*. Metabolomics study of Buyang Huanwu Tang Decoction in ischemic stroke mice by 1H NMR. Metabolomics 2012, 8(5):974-984. https://doi.org:10.1007/s11306-011-0394-0
  59. Chen CT, Peng HP, Jian JW, Tsai KC, Chang JY, Yang EW, Chen JB, Ho SY, Hsu WL, Yang AS*. Protein-protein interaction site predictions with three-dimensional probability distributions of interacting atoms on protein surfaces. PLoS One 2012, 7(6):e37706. https://doi.org:10.1371/journal.pone.0037706
  60. Zhang L, Tsai KC, Du L, Fang H, Li M, Xu W*. How to generate reliable and predictive CoMFA models. Curr Med Chem 2011, 18(6):923-930. https://doi.org:10.2174/092986711794927702
  61. Yang FL, Yang YL, Liao PC, Chou JC, Tsai KC, Yang AS, Sheu F, Lin TL, Hsieh PF, Wang JT, Hua KF, Wu SH*. Structure and immunological characterization of the capsular polysaccharide of a pyrogenic liver abscess caused by Klebsiella pneumoniae: activation of macrophages through Toll-like receptor 4. J Biol Chem 2011, 286(24):21041-21051. https://doi.org:10.1074/jbc.M111.222091
  62. Shie JJ, Fang JM*, Lai PT, Wen WH, Wang SY, Cheng YS, Tsai KC, Yang AS, Wong CH. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. J Am Chem Soc 2011, 133(44):17959-17965. https://doi.org:10.1021/ja207892q
  63. Wen WH, Wang SY, Tsai KC, Cheng YS, Yang AS, Fang JM*, Wong CH. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 2010, 18(11):4074-4084. https://doi.org:10.1016/j.bmc.2010.04.010
  64. Tsai KC, Chen YC, Hsiao NW, Wang CL, Lin CL, Lee YC, Li M*, Wang B*. A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. Eur J Med Chem 2010, 45(4):1544-1551. https://doi.org:10.1016/j.ejmech.2009.12.063
  65. Ho CW, Popat SD, Liu TW, Tsai KC, Ho MJ, Chen WH, Yang AS, Lin CH*. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors. ACS Chem Biol 2010, 5(5):489-497. https://doi.org:10.1021/cb100011u
  66. Yang Q, Du L, Tsai KC, Wang X, Li M*, You Q. Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR & Combinatorial Science 2009, 28(1):59-71. https://doi.org:https://doi.org/10.1002/qsar.200810050
  67. Wang SY, Tseng CP, Tsai KC, Lin CF, Wen CY, Tsay HS, Sakamoto N, Tseng CH, Cheng JC*. Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq. Biochem Biophys Res Commun 2009, 385(2):230-235. https://doi.org:10.1016/j.bbrc.2009.05.043
  68. Tsai KC, Teng LW, Shao YM, Chen YC, Lee YC, Li M, Hsiao NW*. The first pharmacophore model for potent NF-kappaB inhibitors. Bioorg Med Chem Lett 2009, 19(19):5665-5669. https://doi.org:10.1016/j.bmcl.2009.08.021
  69. Tsai KC, Wang SH, Hsiao NW, Li M*, Wang B*. The effect of different electrostatic potentials on docking accuracy: a case study using DOCK5.4. Bioorg Med Chem Lett 2008, 18(12):3509-3512. https://doi.org:10.1016/j.bmcl.2008.05.026
  70. Shao YM, Yang WB, Kuo TH, Tsai KC, Lin CH, Yang AS, Liang PH, Wong CH*. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg Med Chem 2008, 16(8):4652-4660. https://doi.org:10.1016/j.bmc.2008.02.040
  71. Lu IL, Tsai KC, Chiang YK, Jiaang WT, Wu SH, Mahindroo N, Chien CH, Lee SJ, Chen X, Chao YS, Wu SY*. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2008, 43(8):1603-1611. https://doi.org:10.1016/j.ejmech.2007.11.014
  72. Hsu HJ, Tsai KC, Sun YK, Chang HJ, Huang YJ, Yu HM, Lin CH, Mao SS, Yang AS*. Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. J Biol Chem 2008, 283(18):12343-12353. https://doi.org:10.1074/jbc.M708843200
  73. Shie JJ, Fang JM*, Wang SY, Tsai KC, Cheng YS, Yang AS, Hsiao SC, Su CY, Wong CH. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007, 129(39):11892-11893. https://doi.org:10.1021/ja073992i
  74. Shao YM, Yang WB, Peng HP, Hsu MF, Tsai KC, Kuo TH, Wang AH, Liang PH, Lin CH, Yang AS*, Wong CH*. Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. Chembiochem 2007, 8(14):1654-1657. https://doi.org:10.1002/cbic.200700254
  75. Tsai KC, Chen SY, Liang PH, Lu IL, Mahindroo N, Hsieh HP, Chao YS, Liu L, Liu D, Lien W, Lin TH*, Wu SY*. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006, 49(12):3485-3495. https://doi.org:10.1021/jm050852f
  76. Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY*. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem 2006, 49(17):5154-5161. https://doi.org:10.1021/jm060207o
  77. Lin TH*, Chiu SH, Tsai KC. Supervised feature ranking using a genetic algorithm optimized artificial neural network. J Chem Inf Model 2006, 46(4):1604-1614. https://doi.org:10.1021/ci0600354
  78. Zheng ZL, Zuo ZY, Liu ZG, Tsai KC, Liu AF, Zou GL*. Construction of a 3D model of nattokinase, a novel fibrinolytic enzyme from Bacillus natto. A novel nucleophilic catalytic mechanism for nattokinase. J Mol Graph Model 2005, 23(4):373-380. https://doi.org:10.1016/j.jmgm.2004.10.002
  79. Wei HY, Tsai KC, Lin TH*. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. J Chem Inf Model 2005, 45(5):1343-1351. https://doi.org:10.1021/ci050140y
  80. Li MY, Tsai KC, Xia L*. Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett 2005, 15(3):657-664. https://doi.org:10.1016/j.bmcl.2004.11.032
  81. Du LP, Li MY, Tsai KC, You QD, Xia L*. Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochem Biophys Res Commun 2005, 332(3):677-687. https://doi.org:10.1016/j.bbrc.2005.04.165
  82. Tsai KC, Lin TH*. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques. J Chem Inf Comput Sci 2004, 44(5):1857-1871. https://doi.org:10.1021/ci049824g
  83. Liu HC, Lyu PC, Leong MK, Tsai KC, Hsiue GH*. 3D-QSAR studies on PU3 analogues by comparative molecular field analysis. Bioorg Med Chem Lett 2004, 14(3):731-734. https://doi.org:10.1016/j.bmcl.2003.11.024
  84. Lin TH*, Li HT, Tsai KC. Implementing the Fisher's discriminant ratio in a k-means clustering algorithm for feature selection and data set trimming. J Chem Inf Comput Sci 2004, 44(1):76-87. https://doi.org:10.1021/ci030295a
  85. Du LP, Tsai KC, Li MY, You QD, Xia L*. The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett 2004, 14(18):4771-4777. https://doi.org:10.1016/j.bmcl.2004.06.070
  86. Lin TH*, Tsai KC, Lo TC. Homology modeling of the central catalytic domain of insertion sequence ISLC3 isolated from Lactobacillus casei ATCC 393. Protein Eng 2003, 16(11):819-829. https://doi.org:10.1093/protein/gzg107

瀏覽數:
友善列印